Kyungho Choi

Title: Innovations of Kyungho Choi in Cancer Treatment

Introduction

Kyungho Choi is a notable inventor based in Goyang-si, South Korea. He has made significant contributions to the field of cancer treatment through his innovative research and development of chimeric antigen receptors.

Latest Patents

Kyungho Choi holds a patent for a chimeric antigen receptor to which an anti-cotinine antibody is linked. This invention relates to chimeric antibody receptors that utilize anti-cotinine antibodies. The T cells presenting this chimeric antibody receptor can secrete interferon gamma specifically targeting cotinine-conjugated binding molecules. This mechanism induces cell death in cells expressing the target molecule. Additionally, the invention allows for the administration of a cytotoxic agent conjugated with cotinine to remove the chimeric antigen receptor T cells, thereby mitigating immune side effects caused by T cell hyperactivity. This innovative approach offers a safe and effective method for cancer treatment.

Career Highlights

Kyungho Choi is affiliated with Seoul National University, where he continues to advance his research in immunotherapy and cancer treatment. His work has garnered attention for its potential to improve patient outcomes in oncology.

Collaborations

Kyungho Choi collaborates with esteemed colleagues, including Hyung-Bae Park and Ji Eun Lee, who contribute to his research endeavors.

Conclusion

Kyungho Choi's innovative work in developing chimeric antigen receptors represents a significant advancement in cancer therapy. His contributions are paving the way for new treatment options that could enhance the effectiveness and safety of cancer treatments.